VYKAT™

维卡特™

XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in

XR（二氮嗪胆碱）是首个且唯一获得FDA批准的用于治疗过度饥饿的药物

Prader-Willi Syndrome and Represents a Transformative Therapy

Prader-Willi综合征，并代表了一种变革性的治疗方法

Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont)

扩展了Neurocrine的高增长商业产品组合，包括INGREZZA®（valbenazine）和CRENESSITY®（crinecerfont）在内的三种首创药物。

Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040s

为长期收入增长和价值创造建立了一个持久的平台，依托强大的VYKAT XR知识产权资产，预计将持续到2040年代中期。

Neurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction

Neurocrine 将于今天上午 8:00（东部时间）举办电话会议，讨论此次交易。

SAN DIEGO and REDWOOD CITY, Calif.

加利福尼亚州圣地亚哥和红木城

,

，

April 6, 2026

2026年4月6日

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:

/PRNewswire/ -- Neurocrine Biosciences, Inc.（纳斯达克：

NBIX

NBIX

) and Soleno Therapeutics, Inc. (Nasdaq:

）和Soleno Therapeutics, Inc.（纳斯达克：

SLNO

序列号

) today announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion.

）今天宣布，Neurocrine 已经达成一项最终协议，将以每股 53.00 美元的价格收购 Soleno，交易总股权价值达 29 亿美元。

The acquisition of Soleno and the addition of VYKAT™ XR (diazoxide choline), a first-in-class therapy to treat hyperphagia, the defining feature of Prader-Willi syndrome (PWS), will expand Neurocrine's portfolio of innovative medicines and strengthen its leadership position in endocrinology and rare disease.

收购Soleno公司并引入VYKAT™ XR（二氮嗪胆碱），一种用于治疗普拉德-威利综合征（PWS）的显著特征——过度饥饿的首创新疗法，将扩展Neurocrine的创新药物组合，并巩固其在内分泌学和罕见病领域的领导地位。

Since its FDA approval and successful U.S. launch in the second quarter of 2025, VYKAT XR has demonstrated strong early adoption, generating $190 million in 2025 revenue, including $92 million for Soleno in the fourth quarter alone. When supported by Neurocrine's medical and commercial infrastructure, VYKAT XR is expected to continue to improve care for patients with PWS while delivering long-term value to Neurocrine shareholders following the close of the transaction..

自2025年第二季度获得FDA批准并在美国成功上市以来，VYKAT XR展现了强劲的早期采用率，2025年实现收入1.9亿美元，其中仅第四季度就为Soleno带来了9200万美元的收入。在Neurocrine的医疗和商业基础设施支持下，预计VYKAT XR将继续改善PWS患者的治疗效果，并在交易完成后为Neurocrine股东带来长期价值。

'This transaction will advance Neurocrine's mission to deliver life-changing treatments while accelerating our revenue growth and portfolio diversification strategy. We share the Soleno team's deep commitment to the Prader-Willi syndrome community and look forward to leveraging our experience and capabilities to expand VYKAT XR's reach to benefit more patients, while further strengthening Neurocrine's leadership in delivering transformative medicines,' said Kyle W.

“这笔交易将推动Neurocrine实现提供改变生命疗法的使命，同时加速我们的收入增长和产品组合多样化战略。我们与Soleno团队对普拉德-威利综合征患者群体有着深厚的承诺，并期待利用我们的经验和能力，扩大VYKAT XR的覆盖范围，以造福更多患者，同时进一步巩固Neurocrine在提供变革性药物方面的领导地位，”凯尔·W表示。

Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. 'We congratulate Soleno on developing and launching VYKAT XR, showing strong results in a complex disease and enabling broad utilization with a clear label, and we look forward to working together to continue to help patients in need.'.

加诺博士，Neurocrine Biosciences首席执行官表示：“我们祝贺Soleno开发并推出VYKAT XR，在复杂疾病中显示出显著效果，并通过清晰的标签实现广泛使用。我们期待共同努力，继续帮助有需要的患者。”

'Neurocrine is the right strategic partner to expand the reach of VYKAT XR in the Prader-Willi syndrome community given their experience in endocrinology and rare disease and their proven ability to execute successful commercial launches. We are excited to accelerate VYKAT XR's impact for PWS patients following completion of the transaction by leveraging Neurocrine's strong commercial capabilities,' said Anish Bhatnagar, M.D., Chairman and Chief Executive Officer of Soleno..

“鉴于Neurocrine在内分泌学和罕见病领域的经验，以及其成功执行商业发布的成熟能力，他们是扩大VYKAT XR在普拉德-威利综合征社区影响力的理想战略合作伙伴。我们很高兴在交易完成后，通过利用Neurocrine强大的商业能力，加速VYKAT XR对PWS患者的影响力，”Soleno公司董事长兼首席执行官Anish Bhatnagar博士表示。

PWS is a rare genetic neurodevelopmental disorder caused by an abnormality in gene expression on chromosome 15 that affects about 10,000 patients in the United States. The disease is characterized by neurological, behavioral, and metabolic dysfunction. Its defining feature is hyperphagia, a chronic, life-threatening condition marked by a persistent hunger that drives compulsive, food-seeking behavior.

PWS是一种罕见的遗传性神经发育障碍，由15号染色体上的基因表达异常引起，在美国约有10,000名患者受其影响。该疾病以神经、行为和代谢功能障碍为特征。其最显著的特点是贪食症，这是一种慢性、危及生命的状况，表现为持续的饥饿感，驱使患者产生强迫性的觅食行为。

Individuals with PWS also commonly experience cognitive impairment and a range of psychiatric and behavioral challenges. Together, these symptoms can severely diminish quality of life for individuals with PWS and their families, with hyperphagia driving significant morbidity and mortality..

患有PWS的个体还常经历认知障碍以及一系列精神和行为挑战。这些症状共同严重降低了PWS患者及其家庭的生活质量，其中过度饥饿导致了显著的发病率和死亡率。

Strategic Rationale and Financial Benefits of the Transaction

交易的战略理由和财务利益

The transaction is expected to:

该交易预计会：

Strengthen Neurocrine's Leadership in Endocrinology and Rare Disease, and Advance a Diversified Portfolio of First-in-Class Medicines:

加强Neurocrine在内分泌学和罕见病领域的领导地位，并推进多样化的一流药物组合：

Following the completion of the transaction, Neurocrine will have three marketed, first-in-class therapies: INGREZZA®, the vesicular monoamine transmitter 2 (VMAT2) market leader for the treatment of tardive dyskinesia and the chorea associated with Huntington's disease, with $2.51 billion in 2025 revenue; CRENESSITY®, approved in December 2024 for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, with $301 million in 2025 revenue; and VYKAT XR, approved in March 2025 for the treatment of PWS, with $190 million in 2025 revenue for Soleno.

交易完成后，Neurocrine将拥有三种已上市的首创疗法：INGREZZA®，用于治疗迟发性运动障碍和亨廷顿病相关的舞蹈症，是囊泡单胺转运体2（VMAT2）市场的领导者，2025年收入达25.1亿美元；CRENESSITY®，于2024年12月获批用于治疗因21-羟化酶缺乏导致的经典先天性肾上腺增生（CAH），2025年收入为3.01亿美元；以及VYKAT XR，于2025年3月获批用于治疗PWS，2025年为Soleno带来1.9亿美元收入。

Together, these medicines will position Neurocrine to deliver sustained revenue growth through the end of this decade..

这些药物将使Neurocrine能够在本十年末实现持续的收入增长。

Add a First-in-Class Therapy with Durable Value Creation:

添加一个具有持久价值创造的首创疗法：

VYKAT XR is the first and only FDA‑approved therapy for hyperphagia with PWS in the United States. Following a successful launch in 2025, VYKAT XR is well positioned as the foundational first-line therapy for PWS and is supported by a strong intellectual property estate that is expected to extend into the mid-2040s, providing a durable platform for long‑term value creation..

VYKAT XR 是美国首个也是唯一获得 FDA 批准用于治疗 PWS 相关过度饥饿的疗法。在 2025 年成功上市后，VYKAT XR 已成为 PWS 的基础一线治疗方案，并受到强大的知识产权保护支持，预计其专利保护将延续至 2040 年代中期，为长期价值创造提供了持久的平台。

Provide a Transformative Therapy Aligned with Neurocrine's Strategic Focus.

提供与Neurocrine战略重点相符的变革性治疗。

PWS is a neurodevelopmental disorder, and VYKAT XR aligns well with Neurocrine's capabilities addressing diseases at the intersection of neuroscience and endocrinology. Alongside CRENESSITY and an emerging endocrinology portfolio, VYKAT XR will serve as a strong foundation to further build Neurocrine's leadership over time..

PWS是一种神经发育障碍，VYKAT XR与Neurocrine在神经科学和内分泌学交叉领域应对疾病的能力高度契合。与CRENESSITY及不断发展的内分泌产品组合一起，VYKAT XR将成为进一步巩固Neurocrine领导地位的坚实基础。

Enhance Ability to Deliver Long-Term Shareholder Value:

增强长期股东价值的交付能力：

Upon closing, the acquisition of Soleno is expected to contribute to a more diversified and durable revenue base, expand Neurocrine's commercial reach, immediately enhance Neurocrine's growth profile, and increase scale to support sustained innovation and development. This is further supported by continued pipeline progress and disciplined capital allocation.

收购Soleno完成后，预计将为公司带来更加多元化和持久的收入基础，扩大Neurocrine的商业覆盖范围，立即提升Neurocrine的增长前景，并增加规模以支持持续的创新和发展。这一成果还得到了持续推进的管线进展和审慎的资本配置的支持。

Integration of Soleno's operations is expected to drive cost synergies and operational efficiencies as Neurocrine leverages its existing infrastructure..

整合Soleno的运营预计将推动成本协同效应和运营效率，因为Neurocrine利用其现有基础设施。

Transaction Terms and Financing

交易条款与融资

Under the terms of the merger agreement, Neurocrine, through a subsidiary, will commence a cash tender offer to acquire all of the outstanding shares of Soleno's common stock at a price of $53.00 per share, representing a premium of approximately 34% to Soleno's closing share price on April 2, 2026, and a premium of 51% to Soleno's 30-day volume-weighted average price (VWAP).

根据合并协议的条款，Neurocrine将通过一家子公司发起现金要约收购，以每股53.00美元的价格收购Soleno所有已发行的普通股。此价格较Soleno在2026年4月2日的收盘价溢价约34%，较Soleno过去30天的成交量加权平均价格（VWAP）溢价51%。

The consummation of the tender offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Soleno, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary conditions.

要约收购的完成需满足惯例的交割条件，包括至少多数Soleno流通股的要约、1976年《哈特-斯科特-罗迪诺反垄断改进法》规定的等待期届满或终止，以及其他惯例条件。

Following the successful completion of the tender offer, a wholly owned subsidiary of Neurocrine will merge with Soleno and the outstanding Soleno shares not tendered in the tender offer will be converted into the right to receive the same $53.00 per share in cash paid in the tender offer. The transaction will be funded with cash on hand and Neurocrine plans to optimize its capital structure by taking on a modest amount of pre-payable debt.

在成功完成要约收购后，Neurocrine的一家全资子公司将与Soleno合并，未在要约收购中出售的Soleno剩余股份将转换为收取与要约收购中相同的每股53.00美元现金的权利。该交易将由现有现金支付，Neurocrine计划通过承担适量可预付债务来优化其资本结构。

The transaction is not subject to any financing condition..

该交易不受任何融资条件的限制。

The boards of directors of both companies have approved the transaction, which is expected to close within 90 days of this announcement, subject to satisfaction of customary closing conditions, including receipt of regulatory approvals.

两家公司的董事会均已批准该交易，预计将在本公告发布后的 90 天内完成，但须满足惯例的成交条件，包括获得监管机构的批准。

Neurocrine to Host Conference Call Today

Neurocrine今天将举办电话会议

Neurocrine will hold a live conference call and webcast today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). Participants can access the live conference call by dialing 800-579-2543 (US) or 785-424-1789 (International) using the conference ID: NBIX. The webcast and accompanying slides can also be accessed at approximately 7:30 a.m.

Neurocrine 将于今天东部时间上午 8:00（太平洋时间上午 5:00）举行现场电话会议和网络直播。参与者可以通过拨打 800-579-2543（美国）或 785-424-1789（国际），并使用会议 ID：NBIX 来接入现场电话会议。网络直播及配套幻灯片也可以在大约早上 7:30 访问。

Eastern Time on Neurocrine's website under Investors at .

美国东部时间在Neurocrine网站的投资者栏目下。

www.neurocrine.com

www.neurocrine.com

. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

网络广播的重播将在活动结束后大约一小时在网站上提供，并将存档大约一个月。

Advisors

顾问

Goldman Sachs & Co. LLC is serving as exclusive financial advisor and Cooley LLP is serving as legal advisor to Neurocrine. Centerview Partners LLC and Guggenheim Securities, LLC are serving as financial advisors and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel to Soleno..

高盛有限责任公司担任Neurocrine的独家财务顾问，科利律师事务所担任其法律顾问。Centerview Partners有限责任公司和Guggenheim Securities有限责任公司担任Soleno的财务顾问，Wilson Sonsini Goodrich & Rosati专业公司担任其法律顾问。

About INGREZZA® (valbenazine)

关于INGREZZA®（缬苯那嗪）

Please see

请参见

additional safety information

额外的安全信息

, full

，满的

Prescribing Information

处方信息

, including Boxed Warning, and

，包括加框警告，以及

Medication Guide

药品指南

.

。

About CRENESSITY® (crinecerfont)

关于CRENESSITY®（克里内塞方）

Please see

请参见

additional safety information

额外的安全信息

and full

并且充满

Prescribing Information

处方信息

.

。

About Neurocrine Biosciences

关于Neurocrine生物科学公司

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders.

Neurocrine Biosciences是一家领先的生物制药公司，宗旨简单明确：为有重大需求的患者减轻痛苦。我们致力于发现、开发和商业化针对尚未满足需求的神经、精神、内分泌和免疫疾病患者的生活改变性疗法。

The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas.

公司多样化的产品组合包括FDA批准的治疗药物，适应症涵盖迟发性运动障碍、与亨廷顿病相关的舞蹈症、典型的先天性肾上腺皮质增生症、子宫内膜异位症*和子宫肌瘤*，同时还有强大的研发管线，包含多个处于中期至晚期临床开发阶段的化合物，覆盖我们的核心治疗领域。

For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit .

三十年来，我们运用自己对神经科学以及大脑和身体系统之间相互联系的独特见解来治疗复杂疾病。我们不懈地研发药物以减轻衰弱性疾病和病症带来的负担，因为您值得拥有勇敢的科学。欲了解更多信息，请访问。

neurocrine.com

neurocrine.com

, and follow the company on

，并在以下平台关注该公司：

LinkedIn

领英

,

，

X

X

,

，

Facebook

脸书

and

和

YouTube.

YouTube。

(

(

*in collaboration with AbbVie

*与AbbVie合作

)

)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE,

神经内分泌，神经内分泌生物科学标志，你值得拥有勇敢的科学，

INGREZZA

INGREZZA

, and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc.

，CRENESSITY 是 Neurocrine Biosciences, Inc. 的注册商标。

About PWS

关于PWS

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The defining symptom of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense persistent sensation of hunger accompanied by food preoccupations, an extreme drive to consume food, food-related behavior problems, and a lack of normal satiety, which can severely diminish the quality of life for individuals with PWS and their families.

普拉德-威利综合征（PWS）是一种罕见的遗传性神经发育障碍，由15号染色体上的基因表达异常引起。美国普拉德-威利综合征协会估计，PWS在每15,000例活产婴儿中发生一例。PWS的标志性症状是贪食症，这是一种慢性且危及生命的状况，特征为强烈的持续饥饿感，伴随对食物的强迫性关注、极度的进食驱动力、与食物相关的行为问题以及缺乏正常的饱腹感，这些会严重影响PWS患者及其家庭的生活质量。

Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food-seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease..

暴食症可导致显著的死亡率（例如，胃破裂、窒息、因觅食行为导致的意外死亡），长期来看，还会引发糖尿病、肥胖症和心血管疾病等并发症。

INDICATION

适应症

VYKAT XR (diazoxide choline) extended-release tablets is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).

VYKAT XR（二氮嗪胆碱）缓释片适用于治疗4岁及以上患有普拉德-威利综合征（PWS）的成人和儿童患者的过度饥饿症状。

IMPORTANT SAFETY INFORMATION

重要的安全信息

Contraindications

禁忌症

Use of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.

使用VYKAT XR禁忌于已知对二氮嗪、VYKAT XR的其他成分或噻嗪类药物过敏的患者。

Warnings and Precautions

警告和注意事项

Hyperglycemia

高血糖

Hyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia..

高血糖，包括糖尿病酮症酸中毒，已有报道。在开始使用VYKAT XR之前，检测空腹血浆葡萄糖（FPG）和糖化血红蛋白（HbA1c）；对高血糖患者优化血糖控制。在治疗期间，定期监测空腹血糖（FPG或空腹血糖）和糖化血红蛋白（HbA1c）。对于有高血糖风险因素的患者，在治疗的最初几周内应更频繁地监测空腹血糖。

Risk of Fluid Overload

液体过载风险

Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.

据报道，包括与液体过量相关的严重反应在内的水肿已经发生。监测水肿或液体过量的体征或症状。VYKAT XR尚未在心脏储备受损的患者中进行研究，因此在这些患者中应谨慎使用。

Adverse Reactions

不良反应

The most common adverse reactions (incidence ≥10% and at least 2% greater than placebo) included hypertrichosis, edema, hyperglycemia, and rash.

最常见的不良反应（发生率≥10%，且至少比安慰剂高2%）包括多毛症、水肿、高血糖和皮疹。

Please see the full

请参阅完整内容

Prescribing Information, including Medication Guide

处方信息，包括药物指南

.

。

About

关于

Soleno Therapeutics, Inc.

索莱诺治疗公司

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno's first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome.

Soleno 专注于开发和商业化用于治疗罕见病的新型疗法。Soleno 的首个商业产品 VYKAT XR（二氮嗪胆碱）缓释片，前身为 DCCR，是一种每日一次的口服药物，用于治疗 4 岁及以上患有普拉德-威利综合征的成人和儿童的过度饥饿症状。

For more information, please visit .

有关更多信息，请访问。

www.soleno.life

www.soleno.life

.

。

Forward-Looking Statements

前瞻性声明

This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of each of Soleno and Neurocrine, including statements relating to the ability to complete and the timing of completion of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno, Neurocrine, and the other parties thereto (the 'Merger Agreement'), including the anticipated occurrence, manner and timing of the proposed tender offer; the parties' ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation of the subsequent merger set forth in the Merger Agreement; the possibility of any termination of the Merger Agreement; the prospective benefits of the proposed transaction; Neurocrine's strategy, plans, objectives, expectations (financial or otherwise) and intentions with respect to its future financial results and growth potential, anticipated product portfolio, development programs and patent terms; the estimated occurrence of PWS; the estimated U.S.

本通讯包含前瞻性陈述，涉及Soleno和Neurocrine未来事件及未来表现相关的风险和不确定性，包括与2026年4月5日签署的《合并协议和计划》（“合并协议”）相关的交易完成能力及完成时间的陈述，该协议由Soleno、Neurocrine及其他相关方共同达成。这些陈述包括拟议要约收购的预期发生、方式和时间；各方满足合并协议中规定的要约收购完成条件及后续合并完成条件的能力；合并协议可能终止的风险；拟议交易的预期利益；Neurocrine的战略、计划、目标、期望（财务或其他方面）及其对未来财务结果和增长潜力、预期产品组合、开发计划和专利期限的意图；PWS的估计发生率；以及美国市场的相关估算。

population of PWS patients; and other statements that are not historical facts. The forward-looking statements contained in this communication are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements.

PWS患者群体；以及其他非历史事实的陈述。本通讯中包含的前瞻性陈述基于当前的预期和假设，这些预期和假设受风险和不确定性的影响，可能导致实际结果与前瞻性陈述有重大差异。

These statements may contain words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'future,' 'intend,' 'may,' 'opportunity,' 'plan,' 'potential,' 'project,' 'seek,' 'should,' 'strategy,' 'will,' 'would' or other similar words and expressions indicating future results. Risks that may cause these forward-looking statements to be in.

这些声明可能包含诸如“预期”、“相信”、“可能”、“估计”、“预计”、“未来”、“打算”、“会”、“机会”、“计划”、“潜力”、“预计”、“寻求”、“应该”、“策略”、“将”、“会”等词语或其他类似表达未来结果的词语和表述。可能导致这些前瞻性陈述存在的风险包括。

Additional Information about the Acquisition and Where to Find It

关于收购的更多信息及其获取途径

The tender offer for all of the outstanding shares of Soleno described in this communication has not yet commenced. This communication is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Neurocrine and its acquisition subsidiary will file with the SEC upon commencement of the tender offer.

本通讯中描述的对Soleno所有已发行股份的要约收购尚未开始。本通讯仅用于信息目的，不构成推荐，亦非购买或出售任何证券的要约或要约邀请，且不能替代Neurocrine及其收购子公司在要约收购开始时将向美国证券交易委员会提交的要约收购材料。

A solicitation and offer to purchase outstanding shares of Soleno will only be made pursuant to an offer to purchase and related tender offer materials that Neurocrine and its acquisition subsidiary intend to file with the SEC. At the time that the tender offer is commenced, Neurocrine and its acquisition subsidiary will file a tender offer statement on Schedule TO, and Soleno will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.

仅会根据Neurocrine及其收购子公司打算向美国证券交易委员会（SEC）提交的购买要约及相关要约收购材料，进行对Soleno已发行股份的征求和购买要约。在要约收购开始时，Neurocrine及其收购子公司将提交一份TO表格的要约收购声明，而Soleno将针对该要约收购向SEC提交一份14D-9表格的征求/建议声明。

THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF SOLENO ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF SOLENO SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER.

要约收购材料（包括购买要约、相关的转送函及某些其他要约收购文件）以及征集/建议声明将包含有关拟议收购及交易各方的重要信息。SOLENO的投资者和股东被敦促在这些文件可用时（以及每份文件可能不时修订或补充的内容）仔细阅读，因为它们将包含SOLENO投资者和股东在做出任何关于是否在要约收购中出售其普通股的决定前应考虑的重要信息。

The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal) will be made available at no expense on Neurocrine's website at neurocrine.com/investors and (once they becom.

要约收购材料（包括购买要约和相关的转送函）将免费在Neurocrine的网站上提供，网址为neurocrine.com/investors（一旦可用）。

www.sec.gov

www.sec.gov

. Copies of those offer documents and all other documents filed by Neurocrine and Soleno will be made available at no charge by directing a request to the information agent for the tender offer, which will be named in the Schedule TO. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Neurocrine and Soleno each file annual, quarterly, and current reports, proxy statements and other information with the SEC.

这些要约文件的副本以及Neurocrine和Soleno提交的所有其他文件将免费提供，可通过向要约收购的信息代理（其名称将在Schedule TO中列出）提出请求获取。除了购买要约、相关的转送函及某些其他要约收购文件，以及征集/建议声明外，Neurocrine和Soleno还各自向美国证券交易委员会（SEC）提交年度、季度和当前报告、委托书声明及其他信息。

You may read any reports, statements or other information filed by Neurocrine or Soleno with the SEC for free on the SEC's website at .

您可以在SEC的网站上免费阅读Neurocrine或Soleno向SEC提交的任何报告、声明或其他信息。

www.sec.gov

www.sec.gov

.

。

SOURCE Neurocrine Biosciences, Inc.

来源：Neurocrine Biosciences, Inc.

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示